Pulmonary Pharmacology & Therapeutics

Papers
(The H4-Index of Pulmonary Pharmacology & Therapeutics is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Applicability of mouse models for induction of severe acute lung injury56
The promoting role of Cx43 on the proliferation and migration of arterial smooth muscle cells for angiotensin II-dependent hypertension53
Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis40
Editorial Board36
Preliminary study regarding the predicted body weight-based dexamethasone therapy in patients with COVID-19 pneumonia32
Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis31
Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers31
Efficacy and safety of non-prostanoid prostacyclin receptor agonist for pulmonary hypertension: A meta-analysis27
Weight loss in nintedanib-treated patients with idiopathic pulmonary fibrosis25
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)23
Editorial Board22
Editorial Board18
Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry17
Editorial Board17
Enlightening clinical and therapeutic heterogeneity in thoracic actinomycosis: A review in bronchiectasis and non-bronchiectasis patients17
Effect of centrally and peripherally acting GABAB agonism on the healthy human cough reflex16
0.043175935745239